The same conclusion was made by de Jonge et al. [88] who discovered the downregulation of the tumor suppressor gene CDKN2A in older AML patients with intermediate- and unfavorable prognosis. CDKN2A gene encodes a cyclin-dependent kinase inhibitor known as p16(INK4A) protein whose amount increases with physiologic ageing. Here, CDKN2A is linked to acute myeloid leukemia.